Business, energy, technology, markets and global industry news from Business News Today

AKT inhibitor

PharmaDeviceNews AKT inhibitor
Representative image: Targeted prostate cancer treatment enters focus as AstraZeneca’s Truqap approval highlights PTEN-deficient metastatic disease, biomarker testing, and the future of precision oncology.
Medical Devices & Diagnostics

Why AstraZeneca’s Truqap win could force a new testing era in prostate cancer

Find out how AstraZeneca’s Truqap approval could reshape PTEN-deficient prostate cancer treatment and biomarker testing.

Read More
Representative image showing a modern breast cancer consultation as Menarini’s elacestrant and capivasertib data raise fresh questions about oral targeted therapy in metastatic disease.
Pharma & Biotech

Menarini’s ASCO 2026 ELEVATE data raise bigger question on oral oncology combinations

Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?

Read More